Novel Small Molecule Entry Inhibitors of Ebola Virus

Arnab Basu, Debra M. Mills, Daniel Mitchell, Esther Ndungo, John D. Williams, Andrew S. Herbert, John M. Dye, Donald T. Moir, Kartik Chandran, Jean L. Patterson, Lijun Rong, Terry L. Bowlin

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background. The current Ebola virus (EBOV) outbreak has highlighted the troubling absence of available antivirals or vaccines to treat infected patients and stop the spread of EBOV. The EBOV glycoprotein (GP) plays critical roles in the early stage of virus infection, including receptor binding and membrane fusion, making it a potential target for the development of anti-EBOV drugs. We report the identification of 2 novel EBOV inhibitors targeting viral entry. Methods. To identify small molecule inhibitors of EBOV entry, we carried out a cell-based high-throughput screening using human immunodeficiency virus-based pseudotyped viruses expressing EBOV-GP. Two compounds were identified, and mechanism-of-action studies were performed using immunoflourescence, AlphaLISA, and enzymatic assays for cathepsin B inhibition. Results. We report the identification of 2 novel entry inhibitors. These inhibitors (1) inhibit EBOV infection (50% inhibitory concentration, approximately 0.28 and approximately 10 μmol/L) at a late stage of entry, (2) induce Niemann-Pick C phenotype, and (3) inhibit GP-Niemann-Pick C1 (NPC1) protein interaction. Conclusions. We have identified 2 novel EBOV inhibitors, MBX2254 and MBX2270, that can serve as starting points for the development of an anti-EBOV therapeutic agent. Our findings also highlight the importance of NPC1-GP interaction in EBOV entry and the attractiveness of NPC1 as an antifiloviral therapeutic target.

Original languageEnglish (US)
Pages (from-to)S425-S434
JournalJournal of Infectious Diseases
Volume212
DOIs
StatePublished - Oct 1 2015

Fingerprint

Ebolavirus
Glycoproteins
Virus Internalization
Ebola Hemorrhagic Fever
Cathepsin B
Membrane Fusion
Enzyme Assays
Virus Diseases
Inhibitory Concentration 50
Antiviral Agents
Disease Outbreaks
Vaccines

Keywords

  • antiviral
  • Ebola envelope glycoprotein
  • Ebola virus
  • Niemann-Pick C1

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy

Cite this

Basu, A., Mills, D. M., Mitchell, D., Ndungo, E., Williams, J. D., Herbert, A. S., ... Bowlin, T. L. (2015). Novel Small Molecule Entry Inhibitors of Ebola Virus. Journal of Infectious Diseases, 212, S425-S434. https://doi.org/10.1093/infdis/jiv223

Novel Small Molecule Entry Inhibitors of Ebola Virus. / Basu, Arnab; Mills, Debra M.; Mitchell, Daniel; Ndungo, Esther; Williams, John D.; Herbert, Andrew S.; Dye, John M.; Moir, Donald T.; Chandran, Kartik; Patterson, Jean L.; Rong, Lijun; Bowlin, Terry L.

In: Journal of Infectious Diseases, Vol. 212, 01.10.2015, p. S425-S434.

Research output: Contribution to journalArticle

Basu, A, Mills, DM, Mitchell, D, Ndungo, E, Williams, JD, Herbert, AS, Dye, JM, Moir, DT, Chandran, K, Patterson, JL, Rong, L & Bowlin, TL 2015, 'Novel Small Molecule Entry Inhibitors of Ebola Virus', Journal of Infectious Diseases, vol. 212, pp. S425-S434. https://doi.org/10.1093/infdis/jiv223
Basu A, Mills DM, Mitchell D, Ndungo E, Williams JD, Herbert AS et al. Novel Small Molecule Entry Inhibitors of Ebola Virus. Journal of Infectious Diseases. 2015 Oct 1;212:S425-S434. https://doi.org/10.1093/infdis/jiv223
Basu, Arnab ; Mills, Debra M. ; Mitchell, Daniel ; Ndungo, Esther ; Williams, John D. ; Herbert, Andrew S. ; Dye, John M. ; Moir, Donald T. ; Chandran, Kartik ; Patterson, Jean L. ; Rong, Lijun ; Bowlin, Terry L. / Novel Small Molecule Entry Inhibitors of Ebola Virus. In: Journal of Infectious Diseases. 2015 ; Vol. 212. pp. S425-S434.
@article{38c1f12810024e13b802ab327a2007e6,
title = "Novel Small Molecule Entry Inhibitors of Ebola Virus",
abstract = "Background. The current Ebola virus (EBOV) outbreak has highlighted the troubling absence of available antivirals or vaccines to treat infected patients and stop the spread of EBOV. The EBOV glycoprotein (GP) plays critical roles in the early stage of virus infection, including receptor binding and membrane fusion, making it a potential target for the development of anti-EBOV drugs. We report the identification of 2 novel EBOV inhibitors targeting viral entry. Methods. To identify small molecule inhibitors of EBOV entry, we carried out a cell-based high-throughput screening using human immunodeficiency virus-based pseudotyped viruses expressing EBOV-GP. Two compounds were identified, and mechanism-of-action studies were performed using immunoflourescence, AlphaLISA, and enzymatic assays for cathepsin B inhibition. Results. We report the identification of 2 novel entry inhibitors. These inhibitors (1) inhibit EBOV infection (50{\%} inhibitory concentration, approximately 0.28 and approximately 10 μmol/L) at a late stage of entry, (2) induce Niemann-Pick C phenotype, and (3) inhibit GP-Niemann-Pick C1 (NPC1) protein interaction. Conclusions. We have identified 2 novel EBOV inhibitors, MBX2254 and MBX2270, that can serve as starting points for the development of an anti-EBOV therapeutic agent. Our findings also highlight the importance of NPC1-GP interaction in EBOV entry and the attractiveness of NPC1 as an antifiloviral therapeutic target.",
keywords = "antiviral, Ebola envelope glycoprotein, Ebola virus, Niemann-Pick C1",
author = "Arnab Basu and Mills, {Debra M.} and Daniel Mitchell and Esther Ndungo and Williams, {John D.} and Herbert, {Andrew S.} and Dye, {John M.} and Moir, {Donald T.} and Kartik Chandran and Patterson, {Jean L.} and Lijun Rong and Bowlin, {Terry L.}",
year = "2015",
month = "10",
day = "1",
doi = "10.1093/infdis/jiv223",
language = "English (US)",
volume = "212",
pages = "S425--S434",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",

}

TY - JOUR

T1 - Novel Small Molecule Entry Inhibitors of Ebola Virus

AU - Basu, Arnab

AU - Mills, Debra M.

AU - Mitchell, Daniel

AU - Ndungo, Esther

AU - Williams, John D.

AU - Herbert, Andrew S.

AU - Dye, John M.

AU - Moir, Donald T.

AU - Chandran, Kartik

AU - Patterson, Jean L.

AU - Rong, Lijun

AU - Bowlin, Terry L.

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Background. The current Ebola virus (EBOV) outbreak has highlighted the troubling absence of available antivirals or vaccines to treat infected patients and stop the spread of EBOV. The EBOV glycoprotein (GP) plays critical roles in the early stage of virus infection, including receptor binding and membrane fusion, making it a potential target for the development of anti-EBOV drugs. We report the identification of 2 novel EBOV inhibitors targeting viral entry. Methods. To identify small molecule inhibitors of EBOV entry, we carried out a cell-based high-throughput screening using human immunodeficiency virus-based pseudotyped viruses expressing EBOV-GP. Two compounds were identified, and mechanism-of-action studies were performed using immunoflourescence, AlphaLISA, and enzymatic assays for cathepsin B inhibition. Results. We report the identification of 2 novel entry inhibitors. These inhibitors (1) inhibit EBOV infection (50% inhibitory concentration, approximately 0.28 and approximately 10 μmol/L) at a late stage of entry, (2) induce Niemann-Pick C phenotype, and (3) inhibit GP-Niemann-Pick C1 (NPC1) protein interaction. Conclusions. We have identified 2 novel EBOV inhibitors, MBX2254 and MBX2270, that can serve as starting points for the development of an anti-EBOV therapeutic agent. Our findings also highlight the importance of NPC1-GP interaction in EBOV entry and the attractiveness of NPC1 as an antifiloviral therapeutic target.

AB - Background. The current Ebola virus (EBOV) outbreak has highlighted the troubling absence of available antivirals or vaccines to treat infected patients and stop the spread of EBOV. The EBOV glycoprotein (GP) plays critical roles in the early stage of virus infection, including receptor binding and membrane fusion, making it a potential target for the development of anti-EBOV drugs. We report the identification of 2 novel EBOV inhibitors targeting viral entry. Methods. To identify small molecule inhibitors of EBOV entry, we carried out a cell-based high-throughput screening using human immunodeficiency virus-based pseudotyped viruses expressing EBOV-GP. Two compounds were identified, and mechanism-of-action studies were performed using immunoflourescence, AlphaLISA, and enzymatic assays for cathepsin B inhibition. Results. We report the identification of 2 novel entry inhibitors. These inhibitors (1) inhibit EBOV infection (50% inhibitory concentration, approximately 0.28 and approximately 10 μmol/L) at a late stage of entry, (2) induce Niemann-Pick C phenotype, and (3) inhibit GP-Niemann-Pick C1 (NPC1) protein interaction. Conclusions. We have identified 2 novel EBOV inhibitors, MBX2254 and MBX2270, that can serve as starting points for the development of an anti-EBOV therapeutic agent. Our findings also highlight the importance of NPC1-GP interaction in EBOV entry and the attractiveness of NPC1 as an antifiloviral therapeutic target.

KW - antiviral

KW - Ebola envelope glycoprotein

KW - Ebola virus

KW - Niemann-Pick C1

UR - http://www.scopus.com/inward/record.url?scp=84943228616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943228616&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiv223

DO - 10.1093/infdis/jiv223

M3 - Article

C2 - 26206510

AN - SCOPUS:84943228616

VL - 212

SP - S425-S434

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

ER -